Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
October 07, 2019 05:00 ET
|
Pfenex, Inc.
Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019 SAN DIEGO,...
Pfenex to Present at the Cantor Healthcare Conference
September 16, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex to Participate in the Oppenheimer Fall Summit
September 10, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals
September 05, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement...
Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board
September 04, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex Announces Appointment of New Board Member, Lorianne Masuoka, M.D.
August 08, 2019 16:10 ET
|
Pfenex, Inc.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex Reports Second Quarter 2019 Results and Provides Business Update
August 08, 2019 16:05 ET
|
Pfenex, Inc.
NDA for PF708 reached the FDA mid-cycle review milestone in May Positive Phase 1 results for PF743 (JZP-458) and Jazz advances the product to Pivotal Phase 2/3 Study Agreement with Arcellx Leverages...
Pfenex and Arcellx Announce a Development, Evaluation and License Agreement
August 01, 2019 08:10 ET
|
Pfenex, Inc.
First Arcellx sparX protein successfully completed process development using Pfēnex Expression Technology® platform Second sparX program initiated by Arcellx SAN DIEGO, Aug. 01, 2019 (GLOBE...
Pfenex to Announce Second Quarter 2019 Financial Results on August 8
July 25, 2019 16:10 ET
|
Pfenex, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex to Participate at the JMP Securities Life Sciences Conference
June 05, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, June 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...